Knowledge Hub

Manufacturing Of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing

Press release   •   Nov 18, 2016 04:36 EST

GBI Research, the leading business intelligence provider, has released its latest research report, Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing, which provides insights into the production methods of vaccines and into vaccine production capacity. The report discusses the egg-based and cell culture-based vaccine manufacturing processes in depth. Furthermore, details of the whole process throughput and the technologies used in vaccine manufacturing are provided in the report. It also offers a clear view of the regulatory landscapes of the US, Europe and Japan. It includes profiles of the key players and the alliances which exist in the world of vaccine manufacturing. The report explores the emerging technologies, drivers and barriers of the vaccine manufacturing process and the challenges and unmet needs present in the market.

GBI Research analysis suggests that Singapore and China are emerging as the biggest hot spots for the future of vaccine manufacturing, along with India. The vaccine manufacturing market of Singapore is growing at a rate of around 20%. Furthermore, regulatory support from the governments of these three countries is high. The in depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.

GBI Research analysis also gives details of the stakeholders in the vaccine manufacturing industry and their importance within the industry. The major vaccine manufacturers are focused on acquiring new technologies and strengthening their presence in the market, by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. R&D activities also indicate the development of new technologies and novel vaccines that can revolutionize the market in the near future.


The report analyses vaccine manufacturing processes, market characterization, the regulatory landscape and the current scenario of the vaccine manufacturing industry. The report covers the following -

Data and analysis of the global vaccine production capacity as of 2010.

Key drivers and restraints related to the growth of the vaccine manufacturing process.

The Regulatory landscape of the US, Europe and Japan, including the overview of the regulatory authorities in these countries.

The Competitive landscape of the vaccine market, including profiles of the top companies. The companies studied in the report are GlaxoSmithKline, Sanofi Pasteur, Merck, Novartis, Pfizer and CSL Ltd.

Important strategies in vaccine manufacturing, including manufacturing and outsourcing strategies.

Download Sample Copy of Report at

Reasons to buy

The report will help business development and marketing executives strategize their product launches by doing the following -

Build effective strategies by identifying the potential hotspots for vaccine manufacturing.

Develop key strategic initiatives by studying the portfolios of the top players.

Develop vaccine manufacturing expansion strategies by identifying drivers and restraints.

Reinforce market entry and market expansion strategies in the US, Europe and Japan, by exploiting strong growth opportunities.

Formulate strategies to increase your companys growth and develop new solutions for the vaccine manufacturing industry by understanding the current competitive scenario, as well as the challenges and unmet needs facing the vaccine industry.